The lactate production of highly glycolytic other non-IDH mutant cell lines were also tested after in vitro rapamycin treatment in two human Hodgkin lymphoma cells and in another previously metabolically characterised ZR-75.1 human breast carcinoma cell line. This evidence concerns the gene IDH2 and Hodgkins lymphoma.